Post-COVID symptom profiles and duration in a global convalescent COVID-19 observational cohort: Correlations with demographics, medical history, acute COVID-19 severity and global region

作者：Shelly Karuna, Jorge A. Gallardo-Cartagena, Deborah Theodore, Portia Hunidzarira, Juan José Montenegro-Idrogo, Jiani Hu, Megan Jones, Vicky Kim, Robert De La Grecca, Meg Trahey, Carissa Karg, Azwidihwi Takalani, Laura Polakowski, Julia Hütter, Maurine D. Miner, Nathan Erdmann, Paul Goepfert, Rebone Maboa, Lawrence Corey, Katherine Gill, Shuying Sue Li, HVTN 405/HPTN 1901 Study Team · 发表于：Journal of Global Health · 年份：2023 · DOI：10.7189/jogh.13.06020 · 被引用次数：19 · 研究领域：Long-Term Effects of COVID-19、COVID-19 Clinical Research Studies、COVID-19 and Mental Health

Background: Post-COVID conditions are characterised by persistent symptoms that negatively impact quality of life after SARS-CoV-2 diagnosis. While post-COVID risk factors and symptoms have been extensively described in localised regions, especially in the global north, post-COVID conditions remain poorly understood globally. The global, observational cohort study HVTN 405/HPTN 1901 characterises the convalescent course of SARS-CoV-2 infection among adults in North and South America and Africa. Methods: We categorised the cohort by infection severity (asymptomatic, symptomatic, no oxygen requirement (NOR), non-invasive oxygen requirement (NIOR), invasive oxygen requirement (IOR)). We applied a regression model to assess correlations of demographics, co-morbidities, disease severity, and concomitant medications with COVID-19 symptom persistence and duration across global regions. Results: We enrolled 759 participants from Botswana, Malawi, South Africa, Zambia, Zimbabwe, Peru, and the USA a median of 51 (interquartile range (IQR) = 35-66) days post-diagnosis, from May 2020 to March 2021. 53.8% were female, 69.8% were 18-55 years old (median (md) = 44 years old, IQR = 33-58). Comorbidities included obesity (42.8%), hypertension (24%), diabetes (14%), human immunodeficiency virus (HIV) infection (11.6%) and lung disease (7.5%). 76.2% were symptomatic (NOR = 47.4%; NIOR = 22.9%; IOR = 5.8%). Median COVID-19 duration among symptomatic participants was 20 days (IQR = 11-35); 43.4% ...